Potential for Gut Peptide-Based Therapy in Postprandial Hypotension

Borg, Malcolm J.; Xie, Cong; Rayner, Christopher K.; Horowitz, Michael; Jones, Karen L.; Wu, Tongzhi

doi:10.3390/nu13082826

Open AccessReview

Potential for Gut Peptide-Based Therapy in Postprandial Hypotension

by

Malcolm J. Borg

¹,

Cong Xie

¹

,

Christopher K. Rayner

¹,

Michael Horowitz

^1,2,

Karen L. Jones

^1,2

and

Tongzhi Wu

^1,2,*

¹

Adelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide 5000, Australia

²

Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide 5000, Australia

^*

Author to whom correspondence should be addressed.

Nutrients 2021, 13(8), 2826; https://doi.org/10.3390/nu13082826

Submission received: 17 July 2021 / Revised: 6 August 2021 / Accepted: 14 August 2021 / Published: 17 August 2021

(This article belongs to the Special Issue Nutrients and Cardiometabolic Health in Type 2 Diabetes)

Download

Browse Figures

Versions Notes

Abstract

Postprandial hypotension (PPH) is an important and under-recognised disorder resulting from inadequate compensatory cardiovascular responses to meal-induced splanchnic blood pooling. Current approaches to management are suboptimal. Recent studies have established that the cardiovascular response to a meal is modulated profoundly by gastrointestinal factors, including the type and caloric content of ingested meals, rate of gastric emptying, and small intestinal transit and absorption of nutrients. The small intestine represents the major site of nutrient-gut interactions and associated neurohormonal responses, including secretion of glucagon-like peptide-1, glucose-dependent insulinotropic peptide and somatostatin, which exert pleotropic actions relevant to the postprandial haemodynamic profile. This review summarises knowledge relating to the role of these gut peptides in the cardiovascular response to a meal and their potential application to the management of PPH.

Keywords: postprandial hypotension; glucagon-like peptide-1; glucose-dependent insulinotropic polypeptide; somatostatin; diabetes mellitus; autonomic failure

Share and Cite

MDPI and ACS Style

Borg, M.J.; Xie, C.; Rayner, C.K.; Horowitz, M.; Jones, K.L.; Wu, T. Potential for Gut Peptide-Based Therapy in Postprandial Hypotension. Nutrients 2021, 13, 2826. https://doi.org/10.3390/nu13082826

AMA Style

Borg MJ, Xie C, Rayner CK, Horowitz M, Jones KL, Wu T. Potential for Gut Peptide-Based Therapy in Postprandial Hypotension. Nutrients. 2021; 13(8):2826. https://doi.org/10.3390/nu13082826

Chicago/Turabian Style

Borg, Malcolm J., Cong Xie, Christopher K. Rayner, Michael Horowitz, Karen L. Jones, and Tongzhi Wu. 2021. "Potential for Gut Peptide-Based Therapy in Postprandial Hypotension" Nutrients 13, no. 8: 2826. https://doi.org/10.3390/nu13082826

APA Style

Borg, M. J., Xie, C., Rayner, C. K., Horowitz, M., Jones, K. L., & Wu, T. (2021). Potential for Gut Peptide-Based Therapy in Postprandial Hypotension. Nutrients, 13(8), 2826. https://doi.org/10.3390/nu13082826

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Potential for Gut Peptide-Based Therapy in Postprandial Hypotension

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI